Quantbot Technologies LP Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Quantbot Technologies LP acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $435,000.

A number of other hedge funds also recently bought and sold shares of the stock. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $127,344,000. AQR Capital Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after acquiring an additional 304,463 shares during the period. Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $27,834,000. Goldman Sachs Group Inc. raised its position in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after acquiring an additional 209,667 shares in the last quarter. Finally, Saturn V Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $21,962,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Barclays reiterated an “overweight” rating and issued a $224.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday. UBS Group reissued a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $214.38.

Jazz Pharmaceuticals Trading Up 1.9%

Jazz Pharmaceuticals stock opened at $185.40 on Tuesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The stock has a market cap of $11.41 billion, a PE ratio of -31.06, a price-to-earnings-growth ratio of 0.33 and a beta of 0.22. The stock has a 50-day moving average of $171.41 and a two-hundred day moving average of $154.78. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm earned $6.51 earnings per share. The company’s revenue was up 8.1% on a year-over-year basis. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the transaction, the executive vice president owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. This trade represents a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the sale, the senior vice president owned 28,728 shares of the company’s stock, valued at $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 68,015 shares of company stock valued at $13,037,486 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.